PROCEPT BioRobotics Corporation

NasdaqGM:PRCT Voorraadrapport

Marktkapitalisatie: US$4.8b

PROCEPT BioRobotics Toekomstige groei

Future criteriumcontroles 2/6

De verwachting is dat PROCEPT BioRobotics de winst en omzet met respectievelijk 44.3% en 24.6% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 45.8% per jaar.

Belangrijke informatie

44.3%

Groei van de winst

45.8%

Groei van de winst per aandeel

Medical Equipment winstgroei17.1%
Inkomstengroei24.6%
Toekomstig rendement op eigen vermogenn/a
Dekking van analisten

Good

Laatst bijgewerkt14 Nov 2024

Recente toekomstige groei-updates

Recent updates

Earnings Update: Here's Why Analysts Just Lifted Their PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Price Target To US$102

Oct 31
Earnings Update: Here's Why Analysts Just Lifted Their PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Price Target To US$102

Procept BioRobotics: New Hydros Aquablation System To Fuel Next Leg Of Growth

Sep 12

Procept BioRobotics: Risk Capital Unlock With FDA Hydros Approval

Aug 27

Investors Appear Satisfied With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Prospects As Shares Rocket 28%

Aug 25
Investors Appear Satisfied With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Prospects As Shares Rocket 28%

Here's What Analysts Are Forecasting For PROCEPT BioRobotics Corporation (NASDAQ:PRCT) After Its Second-Quarter Results

Aug 04
Here's What Analysts Are Forecasting For PROCEPT BioRobotics Corporation (NASDAQ:PRCT) After Its Second-Quarter Results

PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) P/S Is Still On The Mark Following 37% Share Price Bounce

May 21
PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) P/S Is Still On The Mark Following 37% Share Price Bounce

The Price Is Right For PROCEPT BioRobotics Corporation (NASDAQ:PRCT)

Apr 05
The Price Is Right For PROCEPT BioRobotics Corporation (NASDAQ:PRCT)

US$56.67 - That's What Analysts Think PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Is Worth After These Results

Mar 01
US$56.67 - That's What Analysts Think PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Is Worth After These Results

Despite Lacking Profits PROCEPT BioRobotics (NASDAQ:PRCT) Seems To Be On Top Of Its Debt

Feb 07
Despite Lacking Profits PROCEPT BioRobotics (NASDAQ:PRCT) Seems To Be On Top Of Its Debt

Market Participants Recognise PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Revenues Pushing Shares 26% Higher

Dec 14
Market Participants Recognise PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Revenues Pushing Shares 26% Higher

Is There An Opportunity With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) 43% Undervaluation?

Feb 27
Is There An Opportunity With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) 43% Undervaluation?

Procept Biorobotics announces $52M debt refinancing

Oct 10

Providence announces national contract for PROCEPT Biorobotics Aquabeam Systems

Sep 19

Procept BioRobotics Has Resources To Ramp Up Commercialization

Sep 01

Procept: Leveraging A Novel Water-Based System For Enlarged Prostate Treatment

May 26

Need To Know: Analysts Are Much More Bullish On PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Revenues

May 10
Need To Know: Analysts Are Much More Bullish On PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Revenues

Winst- en omzetgroeiprognoses

NasdaqGM:PRCT - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/2026411-45N/AN/A7
12/31/2025312-71N/AN/A8
12/31/2024223-90N/AN/A8
9/30/2024200-100-104-92N/A
6/30/2024177-104-109-92N/A
3/31/2024156-103-126-104N/A
12/31/2023136-106-133-108N/A
9/30/2023116-107-126-108N/A
6/30/2023102-105-122-109N/A
3/31/202385-98-106-98N/A
12/31/202275-87-83-80N/A
9/30/202261-77-74-72N/A
6/30/202250-69-65-65N/A
3/31/202241-64-61-60N/A
12/31/202134-60-58-57N/A
9/30/202128-57-55-54N/A
6/30/202121-55-53-52N/A
3/31/202114-53-52-52N/A
12/31/20208-53-49-48N/A
12/31/20196-42-51-44N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat PRCT de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat PRCT de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat PRCT de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van PRCT ( 24.6% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.9% per jaar).

Hoge groei-inkomsten: De omzet van PRCT ( 24.6% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.


Groeiprognoses winst per aandeel


Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van PRCT naar verwachting over 3 jaar hoog zal zijn


Ontdek groeibedrijven